LTR Pharma Ltd (ASX: LTP) - Share Price
Current share price for LTP : $0.510 0.015 (3.03%)+
LTR Pharma Ltd (LTP), an ASX-listed company, is a Company that is engaged in improving men's health, physically and mentally, through the commercialisation of an intranasal spray treatment for Erectile Dysfunction (ED).
LTP General Information +
| ASX Code | LTP |
| Website | http://ltrpharma.com |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 92 |
| LTP Share Price | $0.510 |
| Day High | $0.580 |
| Day Low | $0.500 |
| Last Close | $0.495 |
| LTP Share Price Movement | $0.02 ( 3.03% ) |
Prices as at 16:40, 17 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
LTR Pharma Ltd (LTP) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from LTR Pharma Ltd (LTP) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
LTR Pharma Ltd (LTP) price-sensitive announcements
LTP - LTR Executes Definitive U.S. Commercial Agreement with Shed
LTR Pharma Limited has executed a definitive U.S. Commercial Agreement with Shed Holdings
LTR Pharma Ltd (LTP)
17 Jul 2026 | 8:48 AM
17 Jul 2026 | 8:48 AM
LTP - Response to ASX Aware Letter
LTR Pharma Limited responded to an ASX Aware Letter concerning the timing and confidential
LTR Pharma Ltd (LTP)
15 Jun 2026 | 2:16 PM
15 Jun 2026 | 2:16 PM
LTP - LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS
LTR Pharma Limited has executed a binding term sheet with Strive Specialties Inc. to estab
LTR Pharma Ltd (LTP)
11 Jun 2026 | 8:38 AM
11 Jun 2026 | 8:38 AM
LTP - LTR Secures First U.S. Commercial Agreement for ROXUS
LTR Pharma has secured its first U.S. commercial agreement for the distribution of ROXUS®,
LTR Pharma Ltd (LTP)
9 Jun 2026 | 8:35 AM
9 Jun 2026 | 8:35 AM
LTR Pharma Ltd (LTP) Recent ASX Announcements
LTP Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$5.59 | -$3.30 | -33.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$6.95 | -$5.00 | 379.80% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$1.45 | -$1.00 | 40.50% | 0.00 | 0.00 | 0.00% | 0.0% |
LTP Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Clarity Pharmaceuticals Ltd (CU6) | $914M | 0.3002 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| LTR Pharma Ltd (LTP) | $90M | -0.3307 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $2,220M | -0.7857 | 0.0743 | 1.2000 | 75.2471 | 70.0400 | 31.8364 | 0.00% | 0.00% | 0.00% |
LTP Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 2.93 | 0.00 |
| Market | 0.31 | 12.90 | 1.13 | 0.58 |
| Sector | 0.46 | 28.10 | 2.54 | 1.89 |
LTP Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Lee Rodne | Executive Chairman, Executive Director | 7 Oct 2020 |
| Dr Julian John Chick | Non-Executive Director | 25 Nov 2020 |
| Ms Maja Aleksandra McGuire | Non-Executive Director | 6 Sep 2021 |
LTR Pharma Ltd (LTP) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|
See all changes in directors' interest & trades for LTR Pharma Ltd (LTP) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
LTP Management
| Name | Position |
|---|---|
| Euh(David) Hwang | Joint Company Secretary |
| Elizabeth Spooner | Joint Company Secretary |
LTP Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in LTR Pharma Ltd (LTP). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 46,373,750 (30.13%) | LTR Medical Pty Ltd |
LTP Calendar of Events
| Date | Event |
|---|---|
| 25 February 2027 | Report (Interim) |
| 28 August 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
